DNA and RNA Aptamers: From Tools for Basic Research Towards Therapeutic Applications

Henning      Ulrich; Cleber   A.   Trujillo; Arthur   A.   Nery; Janaina   M.   Alves; Paromita      Majumder; Rodrigo   R.   Resende; Antonio   H.   Martins

doi:10.2174/138620706778249695

Abstract

The systematic evolution of ligands by exponential enrichment (SELEX) is a combinatorial oligonucleotide library- based in vitro selection approach in which DNA or RNA molecules are selected by their ability to bind their targets with high affinity and specificity, comparable to those of antibodies. Nucleic acids with high affinity for their targets have been selected against a wide variety of compounds, from small molecules, such as ATP, to membrane proteins and even whole organisms. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands, also known as aptamers, for a wide range of proteins of importance for therapy and diagnostics, such as growth factors and cell surface antigens. The number of aptamers generated as inhibitors of various target proteins has increased following automatization of the SELEX process. Their diagnostic and therapeutic efficacy can be enhanced by introducing chemical modifications into the oligonucleotides to provide resistance against enzymatic degradation in body fluids. Several aptamers are currently being tested in preclinical and clinical trials, and aptamers are in the process of becoming a new class of therapeutic agents. Recently, the anti-VEGF aptamer pegaptanib received FDA approval for treatment of human ocular vascular disease.

Keywords: SELEX, aptamer, therapeutic agent, high-throughput screening

« Previous Next »